Prognostic value of CD44 expression in non-small cell lung cancer: A systematic review

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 7, 2014, Pages 3632-3646

  Luo, Zhuang ^a   Wu, Rong Rong ^a,b   Lv, Liang ^b   Li, Peng ^b   Zhang, Li Yan ^a   Hao, Qing Lin ^a   Li, Wei ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

CD44; CD44 V6; Clinicopathological features; Meta analysis; Non small cell lung cancer (NSCLC); Overall survival; Pancd44

Indexed keywords

CD44 PROTEIN, HUMAN; HERMES ANTIGEN; TUMOR MARKER;

BIOSYNTHESIS; HUMAN; LUNG TUMOR; META ANALYSIS; METABOLISM; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS;

ANTIGENS, CD44; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906254036     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Spira A and Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350: 379-392.
2. Wang J, Wang B, Chen X and Bi J. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Carcino-genesis 2011; 32: 411-416.
3. Nguyen LV, Vanner R, Dirks P and Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012; 12: 133-143.
4. Lee JH, Kim SH, Lee ES and Kim YS. CD24 overexpression in cancer development and progression: a meta-analysis. Oncol Rep 2009; 22: 1149-1156.
5. Wang K, Xu J, Zhang J and Huang J. Prognostic role of CD133 expression in colorectal cancer: a meta-analysis. BMC Cancer 2012; 12: 573.
6. Ni C, Zhang Z, Zhu X, Liu Y, Qu D, Wu P, Huang J and Xu AX. Prognostic value of CD166 expression in cancers of the digestive system: a systematic review and meta-analysis. PLoS One 2013; 8: e70958.
7. Kwong LN and Dove WF. APC and its modifiers in colon cancer. Adv Exp Med Biol 2009; 656: 85-106.
8. van Klaveren RJ, van't Westeinde SC, de Hoop BJ and Hoogsteden HC. Stem cells and the natural history of lung cancer: implications for lung cancer screening. Clin Cancer Res 2009; 15: 2215-2218.
9. Sullivan JP, Minna JD and Shay JW. Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev 2010; 29: 61-72.
10. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT and Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005; 121: 823-835.
11. van der Windt GJ, Schouten M, Zeerleder S, Florquin S and van der Poll T. CD44 is protective during hyperoxia-induced lung injury. Am J Respir Cell Mol Biol 2011; 44: 377-383.
12. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J and Cheng C. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011; 121: 1064-1074.
13. Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, Fink LM, Ma Y and Wong MP. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One 2010; 5: e14062.
14. Su YJ, Lai HM, Chang YW, Chen GY and Lee JL. Direct reprogramming of stem cell properties in colon cancer cells by CD44. EMBO J 2011; 30: 3186-3199.
15. Zhang K, Wang XQ, Zhou B and Zhang L. The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis. Fam Cancer 2013; 12: 449-458.
16. Parmar MK, Torri V and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
17. Lau J, Ioannidis JP and Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-826.
18. Higgins JP and Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
19. Egger M, Davey Smith G, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
20. Clarke MR, Landreneau RJ, Resnick NM, Crowley R, Dougherty GJ, Cooper DL and Yousem SA. Prognostic significance of CD44 expression in adenocarcinoma of the lung. Clin Mol Pathol 1995; 48: M200-204.
21. Hirata T, Fukuse T, Naiki H, Hitomi S and Wada H. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. Cancer Res 1998; 58: 1108-1110.
22. Fukuse T, Hirata T, Naiki H, Hitomi S and Wada H. Expression of proliferating cell nuclear antigen and CD44 variant isoforms in the primary and metastatic sites of nonsmall cell lung carcinoma with intrapulmonary metastases. Cancer 1999; 86: 1174-1181.
23. Pirinen R, Hirvikoski P, Bohm J, Kellokoski J, Moisio K, Viren M, Johansson R, Hollmen S and Kosma VM. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma. Hum Pathol 2000; 31: 1088-1095.
24. Ramasami S, Kerr KM, Chapman AD, King G, Cockburn JS and Jeffrey RR. Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma. J Pathol 2000; 192: 427-432.
25. Zhang HZ, Li HG and Zhang H. Expression of CD44v6 and CEA in non-small cell lung cancer tissue and relationship with prognosis. Guang dong Medical Journal 2001; 22: 911-912.
26. GR Z. The expressions of VEGF, CD44v6 and Ki67 in non-small cell lung carcinoma. Journal of Chongqing Medical University 2003; 28: 473-476.
27. Zhang YC and QY K. Expression of CD44v6 in patients with lung carcinoma and its relationship with lymph node metastasis and prognosis. Actaacademiae Medicine Xuzhou 2003; 23: 325-327.
28. Chen C, Wu YL, Zhou ZM and LJ G. The impact of the expression of multiple genes on the metastasis and survival in resected stage IIIA non2small cell lung cancer (NSCLC) patients. Tumor 2004; 24: 62-64.
29. Zhang L, Meng L, Wang L, Peng Z, Chen J, Wang Z. The clinical significance of detection of vascular endothelial growth factor and CD44v6 expression in human non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2004; 7: 427-430.
30. Liu B, Wang Y and JQ, et al. Expression of Combined Detection on CD44V6 and nm23H1 in Non- small Cell Lung Cancer. Chinese Journal of Clinical Oncology 2005; 32: 784-787.
31. Wu Q, Jiang Y, Min J, Xiang M. Expression of CD44v6 and its prognostic significance in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2005; 8: 215-218.
32. Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O'Byrne KJ, Koong AC and Giaccia AJ. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006; 12: 1507-1514.
33. Li GH, Wu Y and T F. Expression of CD44 gene in non-small cell lung cancer tissue and relationship with prognosis. Journal of Jilin University (Medicine Edition) 2007; 33: 330-334.
34. Weng MX, Wu CH, Yang XP. Expression and Significance of E-Cadherin, CD44v6 and Proliferating Cell Nuclear Antigen in Non-small Cell Lung Cancer. Ai Zheng 2008; 27: 191-195.
35. Xie ZM, Zhu ZH and LJ Z. Expression of proteins related to invasion and metastasis in stage I NSCLC and their prognostic impact. Journal of The Fourth Military Medica 2008; 29: 74-745.
36. Y W. Muc21 mRNA and CD44 mRNA expression and prognosis in non-small cell lung carcinoma. Chinese Journal of Gerontology 2009; 10: 1239-1242.
37. Zhang XH, Luo LP and XL Z. Correlative study among CT signs, prognosis and the expression ofCD44v3 and CD44v6 in peripheral non small cell lung cancer. Chin J Med Imaging Technology 2009; 25: 1195-1198.
38. Meng L, Zhang YD and Wang YB. Clinical significance of vascular endothelial growth factor C and CD44v6 expressions in human non-small cell lung cancer. Journal of Shandong (Health Sciences) 2010; 48: 83-86.
39. Situ D, Long H, Lin P, Zhu Z, Wang J, Zhang X, Xie Z and Rong T. Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma. J Cancer Res Clin Oncol 2010; 136: 1213-1219.
40. Ko YH, Won HS, Jeon EK, Hong SH, Roh SY, Hong YS, Byun JH, Jung CK and Kang JH. Prognostic significance of CD44s expression in resected non-small cell lung cancer. BMC Cancer 2011; 11: 340.
41. Okudela K, Woo T, Mitsui H, Tajiri M, Masuda M, Ohashi K. Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and b-catenin, in primary lung adenocarcinoma-their prognostic significance. Pathol Int 2012; 62: 792-801.
42. Wei MC, Yue SC and QM W. Relation of NM23-H1 and CD44v6 expression to patient's prognosis in the non-small cell lung cancer without lymph node metastasis. Journal of Dalian Medical University 2011; 33: 437-440.
43. Miyoshi T, Kondo K, Hino N, Uyama T and Monden Y. The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer. Clin Cancer Res 1997; 3: 1289-1297.
44. Dai BJ and ZS Z. Expression of CD44V6 in non-small cell lung carcinoma and its significance in prognosis. Journal of Practical Oncology 1998; 4: 214-216.
45. Zhao H, Fang J, Du G. Expression of standard and variant CD44 in human lung cancer. Zhonghua Jie He He Hu Xi Za Zhi 1998; 9: 541-543.
46. Zhao ZS, Ru GQ and Xu WJ. Expressions of CD44V3 and CD44V6 in non small cell lung carcinoma and their significance in prognosis. Chinese Journal of Clinical Oncology and Rehabilitation 1999; 4: 24-27.
47. Wang Z, Zhang H, Li S. Expression and clinical significance of nm232H1 and CD44v6 in non2small cell lung cancer. Zhongguo Fei Ai Za Zhi 2002; 4: 278-281.
48. Sun L, Han J, Yao J, Yang S, Ren Y. Expression and clinicopathological significance of CD44V6 expression in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2000; 1: 48-50.
49. Zuo W, Li H. Relationship of the Expression of CD44v6 and Paxllin to the Prognos is of Non-small Cell Lung Carcinoma. Sichuan Da Xue Xue Bao Yi Xue Ban 2003; 34: 484-485.
50. Gao K, Song GY and Ma Q. Study on Expression of CD44v6, p53, and PCNA Protein in Non small Cell Lung Cancer. Cancer Research on Prevention and Treatment 2003; 93-95.
51. Zhang Q, Wu ES, Chen Q and HZ Y. Expession and prognostic signif icance of CD44v6 and C-erbB-2 in lung carcinomas. China Journal of Modern Medicine 2004; 3: 57-61.
52. Lin H and YQ Y. Expression and significance of CD44v6 in non-small cell lung cancer (NSCLC) specimens. He Long Jiang Medicine and Pharmacy 2005; 4: 13-414.
53. Wu GZ, Zheng XZ, N Z and L G. Expression and significance of PTEN and CD44V6 in human non small cell lung cancer of 50 patients aged over 50 years. Practical Geriatrics 2005; 6: 312-314.
54. Yu J and TC P. Expression and clinicopathologic signif icance of OPN, CD44v6 and MMP22 in squamous cell carcinoma and adenocarcinoma of the lung. Chin J Lung Cancer 2006; 4: 325-328.
55. Yj Y and CD. Expression and clinicopathological signif icance of OPN and CD44v6 in lung cancer. Chin J Lung Cancer 2007; 2: 98-101.
56. Eren B, Sar M, Oz B, Dincbas FH. MMP-2, TIMP-2 and CD44v6 Expression in Non-small-cell Lung Carcinomas. Ann Acad Med Singapore 2008; 37: 32-39.
57. H Y and F Y. The expression and clinical significance of CD44 in non-small cell lung cancer. Journal of Mudanjian Medical University 2010; 4: 16-19.
58. Zhang Y, Wei J, Wang H, Xue X, An Y, Tang D, Yuan Z, Wang F, Wu J, Zhang J and Miao Y. Epithelial mesenchymal transition correlates with CD24+CD44+ and CD133+ cells in pancreatic cancer. Oncol Rep 2012; 27: 1599-1605.
59. Cho SH, Park YS, Kim HJ, Kim CH, Lim SW, Huh JW, Lee JH, Kim HR. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int J Oncol 2012; 4: 211-218.
60. Biddle A, Gammon L, Fazil B and Mackenzie IC. CD44 staining of cancer stem-like cells is influenced by down-regulation of CD44 variant isoforms and up-regulation of the standard CD44 isoform in the population of cells that have undergone epithelial-to-mesenchymal transition. PLoS One 2013; 8: e57314.
61. Fehon RG, Mc Clatchey AI and Bretscher A. Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 2010; 11: 276-287.
62. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011; 11: 254-267.
63. Bourguignon LY, Singleton PA, Diedrich F, Stern R and Gilad E. CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem 2004; 279: 26991-27007.
64. Kim HR, Wheeler MA, Wilson CM, Iida J, Eng D, Simpson MA, Mc Carthy JB and Bullard KM. Hyaluronan facilitates invasion of colon carcinoma cells in vitro via interaction with CD44. Cancer Res 2004; 64: 4569-4576.
65. Yu Q and Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999; 13: 35-48.
66. Nguyen VN, Mirejovsky T, Melinova L and Mandys V. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance. Neoplasma 2000; 47: 400-408.
67. Penno MB, August JT, Baylin SB, Mabry M, Linnoila RI, Lee VS, Croteau D, Yang XL and Rosada C. Expression of CD44 in human lung tumors. Cancer Res 1994; 54: 1381-1387.